Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia.
- 1 November 1993
- journal article
- case report
- Published by BMJ in Archives of Disease in Childhood
- Vol. 69 (5), 577-579
- https://doi.org/10.1136/adc.69.5.577
Abstract
Two children with acute lymphoblastic leukaemia (ALL) taking daily 6-mercaptopurine as part of a national UK therapeutic trial repeatedly developed profound myelosuppression on 25% of the standard protocol dose. Both were found to have undetectable intracellular activity of thiopurine methyltransferase (TPMT), an enzyme controlling one of the major alternative catabolic pathways of 6-mercaptopurine, and both produced higher concentrations of cytotoxic drug metabolites at 10-25% of the protocol dose than other patients taking 100%. It is supposed that these patients represent the 0.33% of the normal population constitutionally lacking TPMT. It is important to recognise such individuals both to avoid fatal bone marrow failure through inadvertent overdosage, and to be reassured that an adequate drug effect can be achieved at around 10% of the standard dose.Keywords
This publication has 13 references indexed in Scilit:
- Is 6-thioguanine more appropriate than 6-mercaptopurine for children with acute lymphoblastic leukaemia?British Journal of Cancer, 1993
- Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipientThe Lancet, 1993
- High-performance liquid chromatographic assay of the methyl and nucleotide metabolites of 6-mercaptopurine: quantitation of red blood cell 6-thioguanine nucleotide, 6-thioinosinic acid and 6-methylmercaptopurine metabolites in a single sampleJournal of Chromatography B: Biomedical Sciences and Applications, 1992
- Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemiaThe Journal of Pediatrics, 1991
- Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia.Journal of Clinical Oncology, 1989
- Pharmacogenetics of acute azathioprine toxicity: Relationship to thiopurine methyltransferase genetic polymorphismClinical Pharmacology & Therapeutics, 1989
- Clinical Pharmacokinetics of AllopurinolClinical Pharmacokinetics, 1986
- Interaction of allopurinol with 6-mercaptopurine and azathioprine.1982
- MERCAPTOPURINE PHARMACOGENETICS - MONOGENIC INHERITANCE OF ERYTHROCYTE THIOPURINE METHYLTRANSFERASE ACTIVITY1980
- Human erythrocyte thiopurine methyltransferase: Radiochemical microassay and biochemical propertiesClinica Chimica Acta; International Journal of Clinical Chemistry, 1978